Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals develops pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery. Products include oral insulin capsule ORMD-0801, in phase III clinical trials for diabetes and NASH treatment. Other products are in phase II trial for type 2 diabetes treatment. The company also licenses COVID-19 and novel coronavirus vaccines. Incorporated in 2002, headquartered in New York.
Overview
Strengths
- Price to book ratio (0.58) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (7.08) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 7.1 |